Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Create Stock SIPAutomate your investments in this
Performance
Open
93.60Prev. Close
93.60Volume
6,575Total traded value
0.06 CrUpper Circuit
112.88Lower Circuit
75.25Fundamentals
| Market Cap | ₹335Cr |
| ROE | 7.74% |
| P/E Ratio(TTM) | 43.84 |
| EPS(TTM) | 2.14 |
| P/B Ratio | 3.23 |
| Dividend Yield | 0.00% |
| Industry P/E | 33.92 |
| Book Value | 29.01 |
| Debt to Equity | 0.38 |
| Face Value | 10 |
Understand Fundamentals
Financials
About Lyka Labs
Lyka Labs is a pharmaceutical company making medicines like injections and creams for domestic and international markets, including the veterinary segment. Its business is guided by a belief in innovation and experimentation to advance its market relevance and product offerings. The company achieved a major financial turnaround, reporting a consolidated net profit of ₹811.40 lakhs against a previous year's loss.;
| Parent Organisation | Lyka Labs |
| Managing Director | Mr. Kunal Gandhi |
| NSE Symbol | LYKALABS |
Shareholding Pattern
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Similar Stocks
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Cohance Lifesciences | NA (0.00%) | 82.27 | ||
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 38.89 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 33.53 | ||
| Wockhardt | NA (0.00%) | -426.40 |